Vesugen (Lys-Glu-Asp) 20mg

What is Vesugen?

Vesugen is a synthetic tripeptide bioregulator with the sequence Lys-Glu-Asp (KED), developed as a defined analogue of short peptides isolated from vascular tissue. It is part of the Khavinson family and is associated in preclinical research with endothelial cells, vascular smooth muscle and the fibroblasts of the vessel wall.

Vesugen (CAS 204271-66-9) extends the Vilon dipeptide by an aspartate residue and forms the core of several longer bioregulators. GenoPept supplies Vesugen UK laboratories as a 20mg lyophilised vial for in-vitro vascular biology research. For background on the whole family, read our guide to Khavinson peptide bioregulators.

Vesugen research applications

Research on this peptide is confined to preclinical settings, chiefly cell culture and rodent models, with a focus on vascular wall and endothelium. The areas below summarise where the published literature has investigated the KED sequence.

Endothelial cell culture

Vesugen has been investigated in cultured endothelial cells, where reported endpoints include proliferation, expression of adhesion molecules and markers of endothelial ageing.

Vascular smooth-muscle and fibroblast models

Research explores whether the KED tripeptide alters proliferation and matrix-protein expression in cultured vascular smooth-muscle cells and dermal fibroblasts.

Vascular ageing in animal models

Preclinical studies examine Vesugen in aged rodents, with outcomes such as vessel-wall histology and transcription of genes associated with senescence and oxidative stress.

Skin and microcirculation research

Some published work extends Vesugen into skin-fibroblast and microvascular models, often alongside Cartalax, to study connective-tissue and vascular ageing together.

Neuronal culture comparisons

Vesugen is occasionally included in neuronal ageing panels with Pinealon to examine whether vascular-derived peptides have overlapping effects on nervous tissue.

Mechanism of action (preclinical)

Vesugen is proposed to act through the nuclear gene-regulation mechanism attributed to Khavinson peptides. The Lys-Glu-Asp sequence is thought to enter cells and bind DNA or histone proteins, modulating transcription of genes involved in endothelial and smooth-muscle cell renewal. In-vitro research reports increased proliferation markers, altered expression of sirtuin-family and senescence-related proteins, and changes in adhesion-molecule expression in cultured vascular cells. These findings are preclinical, and no receptor for the KED tripeptide has been characterised.

Vesugen product specifications

Available sizes

• 20mg vial (lyophilised powder)

This bioregulator is stocked in the UK in a single vial size. Laboratories running larger studies can order bulk boxes of 10 vials at 20–50% off through our bulk and wholesale page.

Reconstitution, handling and storage (laboratory)

Vesugen is supplied as a lyophilised powder and should be reconstituted only under laboratory conditions. Use bacteriostatic water or a sterile diluent appropriate to your assay. Add the solvent slowly down the inside wall of the vial, swirl gently until the powder dissolves and never shake, as agitation can degrade short peptides. Detailed steps are in our guide to reconstituting research peptides.

Unopened vials should be stored at –20 °C for long-term use, or at 2–8 °C for short periods, protected from light. After reconstitution, keep the solution at 2–8 °C and use it within the period stated in your laboratory protocol. See how to store research peptides for a full summary. Wear gloves and eye protection, work in a clean environment and dispose of residues according to local laboratory rules.

Quality assurance and Certificate of Analysis

Purity and identity results are batch-specific. Consult the applicable supplied report for its results and methods; confirm the batch covers current stock and verify the laboratory’s accreditation scope directly.

Related research compounds

• Cardiogen 20mg – the cardiac tetrapeptide that pairs with Vesugen in cardiovascular studies
• Cartalax 20mg – the cartilage tripeptide often co-studied in connective-tissue ageing
• Vilon 20mg – the Lys-Glu dipeptide from which Vesugen extends
• GHK-Cu Copper Peptide – a copper tripeptide studied in angiogenesis and vascular repair models

Vesugen frequently asked questions

What is Vesugen used for in research?

Vesugen is used in laboratory research on endothelial cells, vascular smooth muscle, fibroblasts and vascular ageing. Investigators apply the Lys-Glu-Asp tripeptide to cell cultures and aged animal models to study proliferation, adhesion-molecule expression and senescence-related genes. GenoPept supplies Vesugen strictly for in-vitro research use.

How is Vesugen supplied and tested?

Purity and identity results are batch-specific. Consult the applicable supplied report for its results and methods; confirm the batch covers current stock and verify the laboratory’s accreditation scope directly.

How should Vesugen be stored?

Store unopened Vesugen at minus 20 degrees Celsius for long-term stability, or at 2 to 8 degrees Celsius for short periods protected from light. After reconstitution keep the solution at 2 to 8 degrees Celsius and use within the interval defined by your laboratory protocol. Avoid repeated freeze-thaw cycles.

Is Vesugen for human use?

No. Vesugen is for in-vitro laboratory research only. It is not a medicine, not for human or veterinary use and not for diagnostic or therapeutic purposes. GenoPept does not provide dosing or administration information and sells only for legitimate research in the UK.

How does Vesugen differ from Cardiogen?

Vesugen (Lys-Glu-Asp) is a tripeptide associated with the vascular wall and endothelium, whereas Cardiogen (Ala-Glu-Asp-Arg) is a tetrapeptide associated with cardiac muscle. Both are used in cardiovascular research, but Vesugen is applied to endothelial and smooth-muscle cultures while Cardiogen is applied to cardiomyocyte and myocardial models.

Research use only. Vesugen is sold for in-vitro laboratory research only. It is not for human or veterinary use, not a medicine, and not for diagnostic or therapeutic use. See our research use only policy and UK legal guidance on research peptides.